FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048974830> ?p ?o ?g. }

• W3048974830 endingPage "e0237248" @default.
• W3048974830 startingPage "e0237248" @default.
• W3048974830 abstract "Despite enzalutamide's efficacy in delaying the progression of metastatic castration-resistant prostate cancer (CRPC), resistance to this anti-androgen inevitably occurs. Several studies have revealed that the signal transducer and activator of transcription (STAT) 5 plays a role in tumour progression and development of drug resistance such as enzalutamide. Data mining revealed heterogeneous expression of STAT5 in enzalutamide-treated mCRPC patients and enzalutamide-resistant prostate cancer (PCa). Isobologram analysis revealed that the STAT5 inhibitor pimozide combined with enzalutamide has? additive and synergistic inhibitory effects on cell viability in the used models. Functional analysis with siRNA-mediated STAT5 knockdown yielded divergent results. The LNCaP-derived cell line MR49F could be resensitised to enzalutamide by siRNA-mediated STAT5b-knock-down. In contrast, neither STAT5a nor STAT5b knockdown resensitised enzalutamide-resistant LAPC4-EnzaR cells to enzalutamide. In conclusion, our results indicate that STAT5 may be a possible target in a subgroup of enzalutamide-resistant PCa. However, based on the data presented here, a general role of STAT5 in enzalutamide-resistance and its potential as a therapeutic target could not be shown." @default.
• W3048974830 created "2020-08-21" @default.
• W3048974830 creator A5002485183 @default.
• W3048974830 creator A5007312106 @default.
• W3048974830 creator A5010193379 @default.
• W3048974830 creator A5027278424 @default.
• W3048974830 creator A5034877699 @default.
• W3048974830 creator A5039751847 @default.
• W3048974830 creator A5050943523 @default.
• W3048974830 creator A5053867026 @default.
• W3048974830 creator A5054322548 @default.
• W3048974830 creator A5062125605 @default.
• W3048974830 creator A5072856980 @default.
• W3048974830 creator A5081140133 @default.
• W3048974830 creator A5087601171 @default.
• W3048974830 date "2020-08-13" @default.
• W3048974830 modified "2023-10-18" @default.
• W3048974830 title "Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer" @default.
• W3048974830 cites W1164380865 @default.
• W3048974830 cites W1578291413 @default.
• W3048974830 cites W1582446028 @default.
• W3048974830 cites W1654478997 @default.
• W3048974830 cites W1757407923 @default.
• W3048974830 cites W1854027438 @default.
• W3048974830 cites W1904262082 @default.
• W3048974830 cites W1971763028 @default.
• W3048974830 cites W1971966577 @default.
• W3048974830 cites W1990873225 @default.
• W3048974830 cites W2009061017 @default.
• W3048974830 cites W2010072924 @default.
• W3048974830 cites W2015582646 @default.
• W3048974830 cites W2017757468 @default.
• W3048974830 cites W2020894510 @default.
• W3048974830 cites W2021341670 @default.
• W3048974830 cites W2029368184 @default.
• W3048974830 cites W2051577500 @default.
• W3048974830 cites W2064293531 @default.
• W3048974830 cites W2069303628 @default.
• W3048974830 cites W2080748037 @default.
• W3048974830 cites W2096693293 @default.
• W3048974830 cites W2097382536 @default.
• W3048974830 cites W2099356955 @default.
• W3048974830 cites W2117857186 @default.
• W3048974830 cites W2118304191 @default.
• W3048974830 cites W2121846636 @default.
• W3048974830 cites W2151050931 @default.
• W3048974830 cites W2152206584 @default.
• W3048974830 cites W2157310617 @default.
• W3048974830 cites W2159132187 @default.
• W3048974830 cites W2162411576 @default.
• W3048974830 cites W2165122774 @default.
• W3048974830 cites W2166813346 @default.
• W3048974830 cites W2167749314 @default.
• W3048974830 cites W2168133067 @default.
• W3048974830 cites W2235523093 @default.
• W3048974830 cites W2252849995 @default.
• W3048974830 cites W2271989793 @default.
• W3048974830 cites W2320459985 @default.
• W3048974830 cites W2328135220 @default.
• W3048974830 cites W2412838002 @default.
• W3048974830 cites W2504254225 @default.
• W3048974830 cites W2755751382 @default.
• W3048974830 cites W2767048879 @default.
• W3048974830 cites W2769210969 @default.
• W3048974830 cites W2770044416 @default.
• W3048974830 cites W2810806599 @default.
• W3048974830 cites W2893131726 @default.
• W3048974830 cites W2895926103 @default.
• W3048974830 cites W2922108142 @default.
• W3048974830 cites W2922431983 @default.
• W3048974830 cites W2944403040 @default.
• W3048974830 cites W2950536598 @default.
• W3048974830 cites W2972661946 @default.
• W3048974830 cites W2977137283 @default.
• W3048974830 doi "https://doi.org/10.1371/journal.pone.0237248" @default.
• W3048974830 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7425943" @default.
• W3048974830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32790723" @default.
• W3048974830 hasPublicationYear "2020" @default.
• W3048974830 type Work @default.
• W3048974830 sameAs 3048974830 @default.
• W3048974830 citedByCount "11" @default.
• W3048974830 countsByYear W30489748302020 @default.
• W3048974830 countsByYear W30489748302021 @default.
• W3048974830 countsByYear W30489748302022 @default.
• W3048974830 countsByYear W30489748302023 @default.
• W3048974830 crossrefType "journal-article" @default.
• W3048974830 hasAuthorship W3048974830A5002485183 @default.
• W3048974830 hasAuthorship W3048974830A5007312106 @default.
• W3048974830 hasAuthorship W3048974830A5010193379 @default.
• W3048974830 hasAuthorship W3048974830A5027278424 @default.
• W3048974830 hasAuthorship W3048974830A5034877699 @default.
• W3048974830 hasAuthorship W3048974830A5039751847 @default.
• W3048974830 hasAuthorship W3048974830A5050943523 @default.
• W3048974830 hasAuthorship W3048974830A5053867026 @default.
• W3048974830 hasAuthorship W3048974830A5054322548 @default.
• W3048974830 hasAuthorship W3048974830A5062125605 @default.
• W3048974830 hasAuthorship W3048974830A5072856980 @default.
• W3048974830 hasAuthorship W3048974830A5081140133 @default.

• next